USE IN PREGNANCY
When used in pregnancy, during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ZESTRIL should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.
Lisinopril is an oral long-acting angiotensin converting enzyme inhibitor.
ZESTRIL is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.
ZESTRIL is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis.
Acute Myocardial Infarction
ZESTRIL is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta¬óblockers.
In using ZESTRIL, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that ZESTRIL does not have a similar risk (See WARNINGS).
In considering the use of ZESTRIL, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (See WARNINGS, Anaphylactoid and Possibly Related Reactions).
Published Studies Related to Zestril (Lisinopril)
Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial. [2011.06.15]
BACKGROUND: High blood pressure during acute stroke is associated with poorer stroke outcome. Previous trials have failed to show benefit from lowering blood pressure but treatment may have been commenced too late to be effective... The results will inform the design of a definitive RCT to evaluate the effects of very early blood pressure lowering in acute stroke.
Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients. 
Abstract Background: The present study was designed as an open label, multiple-dose, randomized, parallel trial to evaluate the pharmacodynamic drug-drug interaction of lisinopril and concomitantly administered diclofenac sodium in non-diabetic and diabetic, mild to moderate hypertensive, osteoarthritic patients...
Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study
protocol for a pilot randomised controlled trial. 
BACKGROUND: High blood pressure during acute stroke is associated with poorer
stroke outcome. Previous trials have failed to show benefit from lowering blood
pressure but treatment may have been commenced too late to be effective... The results will inform the design of a definitive RCT
to evaluate the effects of very early blood pressure lowering in acute stroke.
Carotid artery hemodynamics: observing patient-specific changes with amlodipine and lisinopril by using MR imaging computation fluid dynamics. [2010.12]
PURPOSE: To assess whether using magnetic resonance (MR) imaging combined with computational fluid dynamics (CFD) could reveal changes in common carotid artery (CCA) flow and wall shear stress (WSS) that might contribute to differences in CCA remodeling between amlodipine, a calcium channel blocker, and lisinopril, an angiotensin-converting enzyme inhibitor, despite similar reductions in blood pressure (BP)... CONCLUSION: Amlodipine causes increased blood flow and increased time-averaged WSS in the CCA compared with lisinopril, despite similar reductions in BP. Differences in the subacute hemodynamic effects of amlodipine and lisinopril could contribute to the differences in CCA remodeling seen in long-term studies. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10100788/-/DC1. (c) RSNA, 2010
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. [2010.09]
CONCLUSION: Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure.
Clinical Trials Related to Zestril (Lisinopril)
Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition [Completed]
The present study was conducted to find out whether the bioavailability of 10 mg lisinopril
tablets produced by PT Dexa Medica was equivalent to the tablets produced by the innovator
(Zestrilģ 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, under license from Astra
Zeneca UK Ltd.)
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL. [Completed]
This study will be a randomized study investigating the bioequivalence of COREG CR to its
components, COREG and Lisinopril (ZESTRIL). PK samples will be obtained throughout the
study to investigate the PK of COREG CR FDC to COREG and Lisinopril
Comparative Bioavailability Study of Lisinopril Tablets, 10 mg [Completed]
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects [Completed]
To assess if oral nizatidine or lisinopril alone and in combination will increase heme
oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy
A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study [Completed]
Reports of Suspected Zestril (Lisinopril) Side Effects
Drug Ineffective (18),
Drug Hypersensitivity (17),
Drug Dose Omission (9),
Pain (8), more >>
Page last updated: 2013-02-10